• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MARK2/MARK3激酶是人类癌症中YAP/TAZ的催化共依赖因子。

MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer.

作者信息

Klingbeil Olaf, Skopelitis Damianos, Tonelli Claudia, Yoshimoto Toyoki, Alpsoy Aktan, Panepinto Maria C, Minicozzi Francesca, Merrill Joseph R, Cafiero Amanda M, Aggarwal Disha, Russo Suzanne, Ha Taehoon, Demerdash Osama E, Wee Tse-Luen, Spector David L, Lyons Scott K, Tuveson David A, Cifani Paolo, Vakoc Christopher R

机构信息

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

Graduate Program in Genetics, Stony Brook University, Stony Brook, New York.

出版信息

Cancer Discov. 2024 Dec 2;14(12):2471-2488. doi: 10.1158/2159-8290.CD-23-1529.

DOI:10.1158/2159-8290.CD-23-1529
PMID:39058094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609825/
Abstract

The Hippo signaling pathway is commonly dysregulated in human cancer, which leads to a powerful tumor dependency on the YAP/TAZ transcriptional coactivators. In this study, we used paralog cotargeting CRISPR screens to identify kinases MARK2/3 as absolute catalytic requirements for YAP/TAZ function in diverse carcinoma and sarcoma contexts. Underlying this observation is the direct MARK2/3-dependent phosphorylation of NF2 and YAP/TAZ, which effectively reverses the tumor suppressive activity of the Hippo module kinases LATS1/2. To simulate targeting of MARK2/3, we adapted the CagA protein from Helicobacter pylori as a catalytic inhibitor of MARK2/3, which we show can regress established tumors in vivo. Together, these findings reveal MARK2/3 as powerful codependencies of YAP/TAZ in human cancer, targets that may allow for pharmacology that restores Hippo pathway-mediated tumor suppression. Significance: We show how genetic redundancy conceals tight functional relationships between signaling and transcriptional activation in cancer. Blocking the function of MARK2/3 kinases leads to the reactivation of the Hippo tumor suppressive pathway and may have therapeutic potential in YAP/TAZ-dysregulated carcinomas and sarcomas. See related commentary by Gauthier-Coles and Sheltzer, p. 2312.

摘要

河马信号通路在人类癌症中通常失调,这导致肿瘤对YAP/TAZ转录共激活因子产生强烈依赖。在本研究中,我们使用旁系同源共靶向CRISPR筛选来鉴定激酶MARK2/3,它是YAP/TAZ在多种癌和肉瘤环境中发挥功能的绝对催化必需条件。这一观察结果的基础是NF2以及YAP/TAZ直接依赖MARK2/3的磷酸化,这有效地逆转了河马模块激酶LATS1/2的肿瘤抑制活性。为了模拟对MARK2/3的靶向作用,我们改造了幽门螺杆菌的CagA蛋白作为MARK2/3的催化抑制剂,结果表明它可以使体内已形成的肿瘤消退。总之,这些发现揭示了MARK2/3是人类癌症中YAP/TAZ强大的共依赖因子,这些靶点可能有助于开发恢复河马通路介导的肿瘤抑制作用的药理学方法。意义:我们展示了基因冗余如何掩盖癌症中信号传导与转录激活之间紧密的功能关系。阻断MARK2/3激酶的功能会导致河马肿瘤抑制通路的重新激活,并且可能对YAP/TAZ失调的癌和肉瘤具有治疗潜力。见Gauthier-Coles和Sheltzer的相关评论,第2312页。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/072af7e3e52a/cd-23-1529fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/694fa488833b/cd-23-1529fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/f6bedda5f136/cd-23-1529fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/1455e67ec5e0/cd-23-1529fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/85d685ea61c4/cd-23-1529fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/9a7c1cd8b230/cd-23-1529fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/072af7e3e52a/cd-23-1529fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/694fa488833b/cd-23-1529fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/f6bedda5f136/cd-23-1529fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/1455e67ec5e0/cd-23-1529fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/85d685ea61c4/cd-23-1529fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/9a7c1cd8b230/cd-23-1529fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0799/11609825/072af7e3e52a/cd-23-1529fig6.jpg

相似文献

1
MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer.MARK2/MARK3激酶是人类癌症中YAP/TAZ的催化共依赖因子。
Cancer Discov. 2024 Dec 2;14(12):2471-2488. doi: 10.1158/2159-8290.CD-23-1529.
2
Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.Hippo-YAP/TAZ 信号通路在肝细胞癌中的复杂作用。
J Cancer Res Clin Oncol. 2023 Nov;149(16):15311-15322. doi: 10.1007/s00432-023-05272-2. Epub 2023 Aug 22.
3
Hippo pathway-mediated YAP1/TAZ inhibition is essential for proper pancreatic endocrine specification and differentiation.Hippo 通路介导的 YAP1/TAZ 抑制对于胰腺内分泌细胞的正确特化和分化是必需的。
Elife. 2024 Jul 25;13:e84532. doi: 10.7554/eLife.84532.
4
SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.SRCAP 复合物通过重编程 Hippo-YAP/TAZ 信号通路的致癌转录促进肺癌进展。
Cancer Lett. 2024 Mar 31;585:216667. doi: 10.1016/j.canlet.2024.216667. Epub 2024 Jan 26.
5
TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway.靶向TEAD的小分子诱导辅因子转换以调节Hippo信号通路。
Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2425984122. doi: 10.1073/pnas.2425984122. Epub 2025 Jul 3.
6
The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives.Hippo/YAP1 在癌症相关成纤维细胞中的作用:文献综述及未来展望。
Cancer Lett. 2024 Nov 1;604:217244. doi: 10.1016/j.canlet.2024.217244. Epub 2024 Sep 10.
7
YAP/TAZ: An epitome of tumorigenesis.YAP/TAZ:肿瘤发生的一个缩影。
Cancer Lett. 2025 Aug 10;625:217806. doi: 10.1016/j.canlet.2025.217806. Epub 2025 May 15.
8
Activation of Hippo/YAP signaling pathway exacerbates vascular remodeling and aggravates hypertension by upregulating Foxm1.Hippo/YAP信号通路的激活通过上调Foxm1加剧血管重塑并加重高血压。
J Mol Histol. 2025 May 19;56(3):158. doi: 10.1007/s10735-025-10443-1.
9
Bcl-2 dependent modulation of Hippo pathway in cancer cells.Bcl-2 依赖性调节癌细胞中的 Hippo 通路。
Cell Commun Signal. 2024 May 16;22(1):277. doi: 10.1186/s12964-024-01647-1.
10
Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes.二元YAP开启/ YAP关闭癌症类别分子基础及治疗意义
Biochem J. 2025 May 28;482(11):741-61. doi: 10.1042/BCJ20253077.

引用本文的文献

1
Integrative High-Throughput RNAi Screening Identifies BRSK1, STK32C and STK40 as Novel Activators of YAP/TAZ.整合式高通量RNA干扰筛选鉴定出BRSK1、STK32C和STK40为YAP/TAZ的新型激活因子。
Int J Mol Sci. 2025 Aug 13;26(16):7810. doi: 10.3390/ijms26167810.
2
Posttranslational modifications of YAP/TAZ: molecular mechanisms and therapeutic opportunities.YAP/TAZ的翻译后修饰:分子机制与治疗机遇
Cell Mol Biol Lett. 2025 Jul 17;30(1):83. doi: 10.1186/s11658-025-00760-4.
3
Targeting the Hippo pathway in cancer.靶向癌症中的Hippo信号通路。

本文引用的文献

1
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.RAS-GTP 抑制在胰腺癌中的肿瘤选择性活性。
Nature. 2024 May;629(8013):927-936. doi: 10.1038/s41586-024-07379-z. Epub 2024 Apr 8.
2
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer.在癌症中系统性抑制 Hippo 转录输出后的预期和意外影响。
Nat Commun. 2024 Mar 27;15(1):2700. doi: 10.1038/s41467-024-46531-1.
3
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
Nat Rev Drug Discov. 2025 Jun 30. doi: 10.1038/s41573-025-01234-0.
4
Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes.二元YAP开启/ YAP关闭癌症类别分子基础及治疗意义
Biochem J. 2025 May 28;482(11):741-61. doi: 10.1042/BCJ20253077.
5
Mark3 a Prognostic Marker for the Endometrial Cancer.Mark3作为子宫内膜癌的一种预后标志物。
Curr Oncol. 2025 Mar 10;32(3):157. doi: 10.3390/curroncol32030157.
TEAD 抑制克服了 YAP1/TAZ 驱动的 KRASG12C 抑制剂的原发性和获得性耐药。
Cancer Res. 2023 Dec 15;83(24):4112-4129. doi: 10.1158/0008-5472.CAN-23-2994.
4
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.全基因组 CRISPR 筛选鉴定出多个增强 KRASG12C 抑制剂疗效的合成致死靶点。
Cancer Res. 2023 Dec 15;83(24):4095-4111. doi: 10.1158/0008-5472.CAN-23-2729.
5
Sensitive, non-immunogenic imaging of cancer metastases and immunotherapy response.癌症转移和免疫治疗反应的灵敏、非免疫原性成像。
Cell Stress. 2023 Aug 14;7(8):59-68. doi: 10.15698/cst2023.08.288.
6
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.变构泛 TEAD 抑制剂阻断致癌性 YAP/TAZ 信号传导并克服 KRAS G12C 抑制剂耐药性。
Nat Cancer. 2023 Jun;4(6):812-828. doi: 10.1038/s43018-023-00577-0. Epub 2023 Jun 5.
7
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches.YAP/TAZ 作为癌症的主要调控因子:调节、功能和治疗方法。
Nat Cancer. 2023 Jan;4(1):9-26. doi: 10.1038/s43018-022-00473-z. Epub 2022 Dec 23.
8
Hippo signaling instructs ectopic but not normal organ growth.Hippo 信号通路调控组织的异位而非正常生长。
Science. 2022 Nov 18;378(6621):eabg3679. doi: 10.1126/science.abg3679.
9
Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells.药理学阻断 TEAD-YAP 揭示了其在癌细胞中的治疗局限性。
Nat Commun. 2022 Nov 8;13(1):6744. doi: 10.1038/s41467-022-34559-0.
10
The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.通过直接竞争有效破坏YAP-TEAD相互作用的第一类小分子。
ChemMedChem. 2022 Oct 6;17(19):e202200303. doi: 10.1002/cmdc.202200303. Epub 2022 Sep 2.